{
      "Rank": 413,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Conventional therapy plus MenSCs treatment",
            "Conventional therapy plus placebo treatment:\n\nOral or intravenous administration"
      ],
      "ArmGroupInterventionName": [
            "Biological: conventional therapy plus MenSC transplantation",
            "Drug: Conventional therapy plus placebo treatment"
      ],
      "ArmGroupLabel": [
            "Intervention",
            "No intervention"
      ],
      "ArmGroupType": [
            "Experimental",
            "Active Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01483248"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Orthotopic liver transplantation (OLT) is currently the most effective method for end-stage liver diseases. However, the critical shortage of donor organs, high cost, and the problem of immune rejection limit its clinical application, and even some patients on the waiting list will never survive to receive a matched liver. Stem cell transplantation instead of conventional medical therapy or orthotopic liver transplantation will be a promising alternate approach to regenerate damaged hepatic mass. Adult mesenchymal stem cells (MSCs) are generally thought of as an autologous source of regenerative cells in previous studies.In this study, the safety and efficacy of menstrual blood-derived stem cells transplantation for patients with liver cirrhosis will be evaluated."
      ],
      "BriefTitle": [
            "Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER"
      ],
      "CollaboratorName": [
            "Zhejiang University",
            "Zhejiang General Hospital of Armed Police",
            "Zhenjiang First People's Hospital",
            "Wuhan General Hospital of Guangzhou Military Command"
      ],
      "CompletionDate": [
            "October 2015"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Liver Cirrhosis",
            "Fibrosis",
            "Liver Disease",
            "Digestive System Disease"
      ],
      "ConditionAncestorId": [
            "D000010335"
      ],
      "ConditionAncestorTerm": [
            "Pathologic Processes"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC06",
            "All",
            "BC23"
      ],
      "ConditionBrowseBranchName": [
            "Digestive System Diseases",
            "All Conditions",
            "Symptoms and General Pathology"
      ],
      "ConditionBrowseLeafAsFound": [
            "Digestive System Diseases",
            "Digestive System Diseases",
            "Cirrhosis",
            "Liver Cirrhosis",
            "Liver Disease"
      ],
      "ConditionBrowseLeafId": [
            "M8035",
            "M6407",
            "M7637",
            "M10255",
            "M10259"
      ],
      "ConditionBrowseLeafName": [
            "Gastrointestinal Diseases",
            "Digestive System Diseases",
            "Fibrosis",
            "Liver Cirrhosis",
            "Liver Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "high",
            "high"
      ],
      "ConditionMeshId": [
            "D000008103",
            "D000008107",
            "D000004066",
            "D000005767",
            "D000005355"
      ],
      "ConditionMeshTerm": [
            "Liver Cirrhosis",
            "Liver Diseases",
            "Digestive System Diseases",
            "Gastrointestinal Diseases",
            "Fibrosis"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "The purpose of this study is to show whether menstrual blood-derived stem cells can improve the disease conditions in patients with liver cirrhosis.\n\nOne of two treatment arms will be assigned to the patients. One group will receive 2 weeks of conventional therapy plus MenSCs treatment; The other group will receive 2 weeks of conventional therapy plus placebo treatment.\n\nMenSCs will be cultured and collected in a GMP lab. Patients were strictly monitored after the cells injection via i.v.. Patients are followed up at intervals up to at least 2 years.Clinical parameters such as ascites volume,serum alanine aminotransferase,total bilirubin,prothrombin time,albumin,MELD score,and Child-Pugh score will be evaluated at each timepoint."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nWritten informed consent\nAged 20 to 50years\nLiver cirrhosis\nNegative pregnancy test\n\nExclusion Criteria:\n\nPregnant or lactating women\nMalignancies\nSepsis\nVital organs failure\nSevere bacteria infection\nVascular thromboses in the portal or hepatic veins"
      ],
      "EnrollmentCount": [
            "50"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "Female"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000970",
            "D000000998",
            "D000000890",
            "D000002756",
            "D000005765"
      ],
      "InterventionAncestorTerm": [
            "Antineoplastic Agents",
            "Antiviral Agents",
            "Anti-Infective Agents",
            "Cholagogues and Choleretics",
            "Gastrointestinal Agents"
      ],
      "InterventionArmGroupLabel": [
            "Intervention",
            "No intervention"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "All",
            "Hemat",
            "ANeo",
            "Gast"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "All Drugs and Chemicals",
            "Hematinics",
            "Antineoplastic Agents",
            "Gastrointestinal Agents"
      ],
      "InterventionBrowseLeafAsFound": [
            "Inhibitor",
            "Ester"
      ],
      "InterventionBrowseLeafId": [
            "M3466",
            "M10262",
            "M9559",
            "M16481",
            "M3366",
            "M8033"
      ],
      "InterventionBrowseLeafName": [
            "Antiviral Agents",
            "Liver Extracts",
            "Interferons",
            "Ursodeoxycholic Acid",
            "Anti-Infective Agents",
            "Gastrointestinal Agents"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low",
            "high",
            "high",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "patients will receive conventional treatment,such as antiviral drugs, lowering aminotransferase and jaundice medicine.\n\nMenSCs transplantation: taken i.v., twice per week, at a dose of 1*10E6 MSC/kg body for 2 weeks.",
            "25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine."
      ],
      "InterventionMeshId": [
            "D000007372",
            "D000014580"
      ],
      "InterventionMeshTerm": [
            "Interferons",
            "Ursodeoxycholic Acid"
      ],
      "InterventionName": [
            "conventional therapy plus MenSC transplantation",
            "Conventional therapy plus placebo treatment"
      ],
      "InterventionOtherName": [
            "Interferon",
            "Bifendatatum",
            "Ursodeoxycholic Acid",
            "Menstrual blood-derived stem cells(MenSCs)",
            "Interferon",
            "Bifendatatum",
            "Ursodeoxycholic Acid"
      ],
      "InterventionType": [
            "Biological",
            "Drug"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Menstrual blood",
            "Mesenchymal stem cell",
            "Liver cirrhosis"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [
            "Enrolling by invitation"
      ],
      "LastUpdatePostDate": [
            "June 7, 2012"
      ],
      "LastUpdatePostDateType": [
            "Estimate"
      ],
      "LastUpdateSubmitDate": [
            "June 6, 2012"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "S-Evans Biosciences Co., Ltd."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Hangzhou"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "China"
      ],
      "LocationFacility": [
            "the First Affiliated Hospital of Zhejiang University-IRB"
      ],
      "LocationState": [
            "Zhejiang"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "310003"
      ],
      "MaximumAge": [
            "50 Years"
      ],
      "MinimumAge": [
            "20 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Phase 1/2 Study of Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation for the Evaluation of the Efficacy and Safety in Patients With Liver Cirrhosis"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "S-Evans Biosciences Co., Ltd."
      ],
      "OrgStudyId": [
            "SEB-1115-LC"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "S-Evans Biosciences Co., Ltd."
      ],
      "OverallOfficialName": [
            "Charlie Xiang, Professor"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Unknown status"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "October 2013"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [
            "Overall Survival"
      ],
      "PrimaryOutcomeTimeFrame": [
            "48 weeks"
      ],
      "ReferenceCitation": [
            "Houlihan DD, Hopkins LJ, Suresh SX, Armstrong MJ, Newsome PN. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011 Nov;54(5):1891-2; author reply 1892. doi: 10.1002/hep.24722.",
            "Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, Zheng YB, Gao ZL. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011 Sep 2;54(3):820-8. doi: 10.1002/hep.24434. Epub 2011 Jul 14.",
            "Forbes SJ, Newsome PN. New horizons for stem cell therapy in liver disease. J Hepatol. 2012 Feb;56(2):496-9. doi: 10.1016/j.jhep.2011.06.022. Epub 2011 Jul 26. Review.",
            "Nikeghbalian S, Pournasr B, Aghdami N, Rasekhi A, Geramizadeh B, Hosseini Asl SM, Ramzi M, Kakaei F, Namiri M, Malekzadeh R, Vosough Dizaj A, Malek-Hosseini SA, Baharvand H. Autologous transplantation of bone marrow-derived mononuclear and CD133(+) cells in patients with decompensated cirrhosis. Arch Iran Med. 2011 Jan;14(1):12-7. doi: 011141/AIM.004.",
            "Zhang D, Jiang M, Miao D. Transplanted human amniotic membrane-derived mesenchymal stem cells ameliorate carbon tetrachloride-induced liver cirrhosis in mouse. PLoS One. 2011 Feb 4;6(2):e16789. doi: 10.1371/journal.pone.0016789."
      ],
      "ReferencePMID": [
            "21987440",
            "21608000",
            "21798218",
            "21194255",
            "21326862"
      ],
      "ReferenceType": [
            "background",
            "background",
            "background",
            "background",
            "background"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "such as fever,anaphylaxis,cough,chest distress,and dyspnea,et al."
      ],
      "SecondaryOutcomeMeasure": [
            "Liver function improvement",
            "Complications",
            "The improvement of ascites after 12-week treatment",
            "Child-Pugh score",
            "MELD score",
            "SF36-quality of life"
      ],
      "SecondaryOutcomeTimeFrame": [
            "48 weeks",
            "48 weeks",
            "48 weeks",
            "48 weeks",
            "48 weeks",
            "48 weeks"
      ],
      "SeeAlsoLinkLabel": [
            "North American Indian childhood cirrhosis",
            "Cirrhosis",
            "Related Info"
      ],
      "SeeAlsoLinkURL": [
            "http://ghr.nlm.nih.gov/",
            "http://www.nlm.nih.gov/medlineplus/",
            "http://www.fda.gov/"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "October 2010"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "June 2012"
      ],
      "StdAge": [
            "Adult"
      ],
      "StudyFirstPostDate": [
            "December 1, 2011"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "November 23, 2011"
      ],
      "StudyFirstSubmitQCDate": [
            "November 29, 2011"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}